Novel Targeted Nanomedicine for Metastatic Prostate Cancer - CDF12-002

Al-Jamal, Wafa (Principal Investigator)

School of Pharmacy

Status	Finished
Effective start/end date	31/03/14 → 1/08/17

Funding

Prostate Cancer UK: £422,062.00

3 Article

Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy
Silva, V. & Al-Jamal, W. T., 10 May 2017, In: Journal of Controlled Release. 253, p. 82–96
Research output: Contribution to journal › Article › peer-review

Open Access
File

63 Citations (Scopus)

4 Downloads (Pure)
Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy
Hodgins, N. O., Al-Jamal, W. T., Wang, J. T-W., Klippstein, R., Sosabowski, J. K., Marshall, J. F., Maher, J. & Al-Jamal, K. T., 28 Jun 2017, In: Journal of Controlled Release. 256, p. 141-152 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File

19 Citations (Scopus)

5 Downloads (Pure)
Cationic liposome- multi-walled carbon nanotubes hybrids for dual siPLK1 and doxorubicin delivery in vitro
Pereira, S., Lee, J., Rubio, N., Hassan, H. A. F. M., Suffian, I. B. M., Wang, J. T. W., Klippstein, R., Ballesteros, B., Al-Jamal, W. T. & Al-Jamal, K. T., Oct 2015, In: Pharmaceutical Research. 32, 10, p. 3293-3308 16 p.
Research output: Contribution to journal › Article › peer-review

File

26 Citations (Scopus)

4 Downloads (Pure)